Men's Health, Testosterone & Sexual Function • ICD-10-CM N52.33
Erectile dysfunction following urethral surgery
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N52.33 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Erectile dysfunction following urethral surgery Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as N52.33, Erectile dysfunction following urethral surgery falls under Men's Health & TRT management, where PDE5 vascular therapy [Erectile dysfunction following urethral surgery N52.33] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry N52.33: Erectile dysfunction following urethral surgery is managed within Men's Health & TRT.
- 3 Typical cash cost range: Workup highlights for Erectile dysfunction following urethral surgery (N52.33): PDE5 vascular therapy [Erectile dysfunction following urethral surgery N52.33].
- 4 Top reported side effects / signs: Objective lab/clinical target for Erectile dysfunction following urethral surgery: LH, FSH & in Erectile dysfunction following urethral surgery (N52.33: SHBG) (LH/FSH 2.5 – 8.0 mIU/mL (N52.33)) and Hematocrit & Total in Erectile dysfunction following urethral surgery (N52.33: PSA).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Erectile dysfunction following urethral surgery
What Is Erectile dysfunction following urethral surgery?
Designated in federal medical registries as N52.33, Erectile dysfunction following urethral surgery falls under Men's Health & TRT management, where PDE5 vascular therapy [Erectile dysfunction following urethral surgery N52.33] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in men's health & trt, Erectile dysfunction following urethral surgery (N52.33) involves impaired cavernosal endothelial in Erectile dysfunction following urethral surgery (N52.33: nitric oxide-cGMP smooth-muscle). progression correlates with shifts in LH, FSH & in Erectile dysfunction following urethral surgery (N52.33: SHBG) (LH/FSH 2.5 – 8.0 mIU/mL (N52.33)).
Common Symptoms & Clinical Signs
- • Presentation of Erectile dysfunction following urethral surgery (N52.33): reduced sexual desire, in Erectile dysfunction following urethral surgery (N52.33: fewer spontaneous morning)
- • Secondary Erectile dysfunction following urethral surgery clinical sign: loss of lean in Erectile dysfunction following urethral surgery (N52.33: muscle recovery, rising)
- • Symptom flares in Erectile dysfunction following urethral surgery correlating with LH, FSH & in Erectile dysfunction following urethral surgery (N52.33: SHBG) deviation outside LH/FSH 2.5 – 8.0 mIU/mL (N52.33)
- • Functional men's health & trt impact requiring PDE5 vascular therapy [Erectile dysfunction following urethral surgery N52.33] evaluation (N52.33)
Erectile dysfunction following urethral surgery Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N52.33 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NLM Clinical Tables |
| Diagnostic / Lab Marker: LH, FSH & in Erectile dysfunction following urethral surgery (N52.33: SHBG) | LH/FSH 2.5 – 8.0 mIU/mL (N52.33) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hematocrit & Total in Erectile dysfunction following urethral surgery (N52.33: PSA) | Hct < 50%; age-appropriate PSA (N52.33) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Erectile dysfunction following urethral surgery (N52.33: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (N52.33) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Erectile dysfunction following urethral surgery
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Cefazolin Cefazolin Generic • RxCUI 1665050 | Cephalosporin Antibacterial | 77% | $0.9744 | $ 47.96 /mo |
| Iodixanol Visipaque • RxCUI RXN-65219381-1723 | Radiographic Contrast Agent | 87% | $3.2500 | $ 140.13 /mo |
| Ultramicrosize Griseofulvin Ultramicrosize Griseofulvin Generic • RxCUI 239239 | Tubulin Inhibiting Agent | 79% | $2.6518 | $ 115.90 /mo |
| Cefaclor Ceclor • RxCUI 197449 | Cephalosporin Antibacterial | 86% | $0.8733 | $ 18.35 /mo |
| Cefepime Cefepime Generic • RxCUI 1665088 | Cephalosporin Antibacterial | 77% | $3.7308 | $ 159.60 /mo |
| Amphotericin B Amphotericin B Generic • RxCUI 967385 | Lipid-based Polyene Antifungal | 81% | $1.6500 | $ 75.33 /mo |
| Ioversol Optiray 320, Optiray • RxCUI RXN-00191323-1726 | Radiographic Contrast Agent | 83% | $2.8200 | $ 122.71 /mo |
| Diltiazem Hci Diltiazem Hci Generic • RxCUI 1791240 | Calcium Channel Blocker | 94% | $0.0935 | $ 12.29 /mo |
| Sertraline Hydrochloride Sertraline HCl, Zoloft • RxCUI 312941 | Serotonin Reuptake Inhibitor | 89% | $0.0496 | $ 5.64 /mo |
| Quizartinib Vanflyta • RxCUI 2643054 | Kinase Inhibitor | 77% | $3.3600 | $ 144.58 /mo |
| Itraconazole Tolsura, Sporanox • RxCUI 311204 | Azole Antifungal | 89% | $0.7974 | $ 16.80 /mo |
| Fludeoxyglucose F-18 Fludeoxyglucose F18 • RxCUI RXN-24450647-1722 | Radioactive Diagnostic Agent | 83% | $2.7500 | $ 119.88 /mo |
| Oxiconazole Nitrate Oxistat • RxCUI 312139 | Azole Antifungal | 86% | $2.7247 | $ 93.93 /mo |
| Penicillin G Benzathin Lentocilin • RxCUI 2671687 | Penicillin-class Antibacterial | 82% | $0.0442 | $ 10.29 /mo |
| Adenosine Tissen NF 10, Tissen Icm 10 • RxCUI 1654169 | Adenosine Receptor Agonist | 91% | $2.0100 | $ 89.91 /mo |
| Vancomycin Tyzavan, Vancocin HCl • RxCUI 1807508 | Glycopeptide Antibacterial | 90% | $0.3416 | $ 22.25 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erectile dysfunction following urethral surgery)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone Replacement Therapy on Lower Urinary Tract: What a 2,029-Participant Study Found In this meta-analysis of 14 clinical trials of TRT for LOH, the change in IPSS was similar among men receiving TRT versus placebo, suggesting that TRT treatment does not worsen LUTS among men with LOH. European urology • 2016-06-15 • Meta-Analysis | N = 2,029 | 99/100 | PMID 26874809 ↗ |
| New Insights on Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile: What a 1,458-Participant Study Found TTh achieved a significant improvement in the IIEF-EFD score of hypogonadal men compared with placebo, especially in those who received testosterone gel, were treated for over 30 weeks, and had no comorbidities. Urologia internationalis • 2022-01-15 • Meta-Analysis | N = 1,458 | 99/100 | PMID 34856556 ↗ |
| New Insights on Effect of testosterone replacement therapy on fracture risk in hypogonadal: What a 2,711-Participant Study Found TRT is associated with an increased incidence of predominantly non-major fractures, while the risk of major osteoporotic fractures, including hip and vertebral fractures, was not increased. Maturitas • 2026-06-15 • Meta-Analysis | N = 2,711 | 99/100 | PMID 42066666 ↗ |
| New Insights on Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With: What a 5,204-Participant Study Found A total of 5204 men were included, 815 with anemia (mean [SD] age, 64.8 [7.7] years; 247 Black [30.3%], 544 White [66.7%], 24 other [2.9%]) and 4379 without anemia (mean [SD] age, 63.0 [7.9] years; 629 Black [14.4%], 3603... JAMA network open • 2023-10-02 • Randomized Controlled Trial | N = 5,204 | 96/100 | PMID 37889486 ↗ |
| Combination Therapies vs. Single-drug treatment: Which Works Better for Erectile Dysfunction? A total of 44 studies included 3853 men with a mean (SD) age of 55.8 (11.9) years. JAMA network open • 2021-02-01 • Meta-Analysis | N = 3,853 | 94/100 | PMID 33599772 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Erectile dysfunction following urethral surgery Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Erectile dysfunction following urethral surgery community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Erectile dysfunction following urethral surgery.
Related Conditions in Men's Health, Testosterone & Sexual Function
Male Hypogonadism & Androgen Deficiency
ICD-10 E29.1
Vasculogenic Erectile Dysfunction & Lower Urinary Tract BPH
ICD-10 N52.9
Erectile Dysfunction
ICD-10 N52.9
Hormones
ICD-10 E29.1
Safety
ICD-10 E29.6
Sexual Problems in Men
ICD-10 N52.5
Hypogonadism - male
ICD-10 E29.1
Testicular hyperfunction
ICD-10 E29.0